» Articles » PMID: 39125612

Molecular Morbidity Score-Can MicroRNAs Assess the Burden of Disease?

Overview
Journal Int J Mol Sci
Publisher MDPI
Date 2024 Aug 10
PMID 39125612
Authors
Affiliations
Soon will be listed here.
Abstract

Multimorbidity refers to the presence of two or more chronic diseases and is associated with adverse outcomes for patients. Factors such as an ageing population have contributed to a rise in prevalence of multimorbidity globally; however, multimorbidity is often neglected in clinical guidelines. This is largely because patients with multimorbidity are systematically excluded from clinical trials. Accordingly, there is an urgent need to develop novel biomarkers and methods of prognostication for this cohort of patients. The hallmarks of ageing are now thought to potentiate the pathogenesis of multimorbidity. MicroRNAs are small, regulatory, noncoding RNAs which have been implicated in the pathogenesis and prognostication of numerous chronic diseases; there is a substantial body of evidence now implicating microRNA dysregulation with the different hallmarks of ageing in the aetiology of chronic diseases. This article proposes using the hallmarks of ageing as a framework to develop a panel of microRNAs to assess the prognostic burden of multimorbidity. This putative molecular morbidity score would have many potential applications, including assessing the efficacy of clinical interventions, informing clinical decision making and facilitating wider inclusion of patients with multimorbidity in clinical trials.

References
1.
Li X, Han Y, Meng Y, Yin L . Small RNA-big impact: exosomal miRNAs in mitochondrial dysfunction in various diseases. RNA Biol. 2024; 21(1):1-20. PMC: 10773649. DOI: 10.1080/15476286.2023.2293343. View

2.
Rosas-Alonso R, Galera R, Sanchez-Pascuala J, Casitas R, Burdiel M, Martinez-Ceron E . Hypermethylation of Anti-oncogenic MicroRNA 7 is Increased in Emphysema Patients. Arch Bronconeumol (Engl Ed). 2019; 56(8):506-513. DOI: 10.1016/j.arbres.2019.10.017. View

3.
Harrison C, Fortin M, van den Akker M, Mair F, Calderon-Larranaga A, Boland F . Comorbidity versus multimorbidity: Why it matters. J Multimorb Comorb. 2021; 11:2633556521993993. PMC: 7930649. DOI: 10.1177/2633556521993993. View

4.
Unger J, Hershman D, Fleury M, Vaidya R . Association of Patient Comorbid Conditions With Cancer Clinical Trial Participation. JAMA Oncol. 2019; 5(3):326-333. PMC: 6439841. DOI: 10.1001/jamaoncol.2018.5953. View

5.
Huang S, Xiao X, Wu H, Zhou F, Fu C . MicroRNA-582-3p knockdown alleviates non-alcoholic steatohepatitis by altering the gut microbiota composition and moderating TMBIM1. Ir J Med Sci. 2023; 193(2):909-916. DOI: 10.1007/s11845-023-03529-w. View